LADENBURG THALM/SH SH Initiates Coverage on Fractyl Health (NASDAQ:GUTS)

Key Points

• LADENBURG THALM/SH SH has initiated coverage on Fractyl Health (NASDAQ:GUTS) with a buy rating and a price target of $3.60, indicating a potential upside of 263.64%.
• Fractyl Health reported a quarterly EPS of ($0.53), which missed estimates by ($0.16), and has a negative return on equity of 584.35%.
• Several hedge funds have recently increased their positions in Fractyl Health, with notable purchases including Catalyst Funds Management and Jane Street Group totaling new investments around $26,000 to $34,000.

Equities researchers at LADENBURG THALM/SH SH started coverage on shares of Fractyl Health (NASDAQ:GUTS - Get Free Report) in a report released on Thursday,Benzinga reports. The brokerage set a "buy" rating and a $3.60 price target on the stock. LADENBURG THALM/SH SH's target price would indicate a potential upside of 263.64% from the stock's current price.

Separately, Canaccord Genuity Group reduced their price target on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $6.53.

Fractyl Health Trading Down 2.0%

NASDAQ:GUTS opened at $0.99 on Thursday. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 4.61. The stock has a market capitalization of $49.79 million, a price-to-earnings ratio of -0.48 and a beta of 1.66. The firm has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $1.50. Fractyl Health has a 12 month low of $0.83 and a 12 month high of $3.72.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Fractyl Health had a negative return on equity of 584.35% and a negative net margin of 73,864.52%. Analysts expect that Fractyl Health will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GUTS. Catalyst Funds Management Pty Ltd purchased a new position in Fractyl Health during the second quarter worth about $26,000. Jane Street Group LLC purchased a new position in Fractyl Health during the second quarter worth about $31,000. Raymond James Financial Inc. purchased a new position in Fractyl Health during the fourth quarter worth about $34,000. Chicago Partners Investment Group LLC purchased a new position in Fractyl Health during the first quarter worth about $37,000. Finally, HighTower Advisors LLC boosted its holdings in Fractyl Health by 57.9% during the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock worth $49,000 after purchasing an additional 15,000 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.